Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Why the Youth Enrichment Services Market Is Growing (and Recession Resilient)

    As parents increasingly look to provide their kids with an edge, the youth enrichment sector is booming—and emerging as a highly compelling investment category.

    Read more

  • Joe Schauenberg Joins THL Partners’ Healthcare in Action Podcast

    Joe Schauenberg, head of healthcare IT investment banking, was recently featured on THL Partners’ Healthcare in Action, a podcast that explores the latest developments and innovations transforming the healthcare sector.

    Read more

  • Cameco Corporation: Initiation of Research Coverage

    William Blair initiated research coverage of Cameco Corporation (CCJ $120.27), a global leader in uranium mining, refining, and conversion.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures